3-(4'-chloro-biphenyl-4-yl)-acrylic acid | 83281-26-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(4'-chloro-biphenyl-4-yl)-acrylic acid
• 英文别名: 3-[4-(4-Chlorophenyl)phenyl]prop-2-enoic acid
• CAS: 83281-26-9
• 化学式: C₁₅H₁₁ClO₂
• 分子量: 258.704
• InChiKey: AZQVAMURVZRSHY-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120 °C(Solv: acetic acid (64-19-7); water (7732-18-5))
• 沸点：
  437.3±33.0 °C(Predicted)
• 密度：
  1.278±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(4'-chloro-biphenyl-4-yl)-acrylic acid 在 溴 、 1-羟基苯并三唑 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 2,3-dibromo-3-(4'-chloro-biphenyl-4-yl)-N-(4-piperidin-1-ylmethyl-phenyl)-propionamide
  参考文献：
  名称：

  Design, synthesis and evaluation of MCH receptor 1 antagonists—Part II: Optimization of pyridazines toward reduced phospholipidosis and hERG inhibition

  摘要：

  Despite recent success there remains a high therapeutic need for the development of drugs targeting diseases associated with the metabolic syndrome. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, a series of 3,6-disubstituted pyridazines was evaluated. During optimization several issues of the initial lead structures had to be resolved, such as selectivity over related GPCRs, inhibition of the hERG channel as well as the potential to induce phospholipidosis. Utilizing property-based design, we could demonstrate that all parameters can significantly be improved by consequently increasing the polarity of the compounds. By this strategy, we succeeded in identifying potent and orally available MCH-R1 antagonists with good selectivity over M1 and 5-HT2A and an improved safety profile with respect to hERG inhibition and phospholipidosis. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.05.074
• 作为产物：
  描述：

  4-(4-chlorophenyl)benzenediazonium chloride 在 CuCl₂*2H₂O 氢氧化钾 作用下， 以 乙醇 、 水 、 丙酮 为溶剂， 反应 10.0h， 生成 3-(4'-chloro-biphenyl-4-yl)-acrylic acid
  参考文献：
  名称：

  Ganushchak, N. I.; Fedorovich, I. S.; Obushak, N. D., Journal of Organic Chemistry USSR (English Translation), 1982, vol. 18, p. 1508 - 1512

  摘要：

  DOI：

文献信息

• [DE] 3-(4-PIPERIDIN-1YLMETHYL-PHENYL) -PROPIONSÄURE-PHRNYLAMID-DERIVATE UND VERWANDTE VERBINDUNGEN ALS MCH (MELANINE CONCENTRATING HORMONE) ANTAGONISTEN ZUR BEHANDLUNG VON ESSSTÖRUNGEN<br/>[EN] 3-(4-PIPERIDINE-1YLMETHYL-PHENYL)-PROPION ACID-PHENYLAMIDE-DERIVATIVES AND RELATED COMPOUNDS USED IN THE FORM OF MCH ANTAGONISTS (MELANINE CONCENTRATING HORMONE) FOR TREATING EATING DISORDERS<br/>[FR] DERIVES D'ACIDE 3-(4-PIPERIDINE-1YLMETHYL-PHENYL) PROPIONIQUE-PHENYLAMIDE ET COMPOSES APPARENTES, UTILISES COMME ANTAGONISTES MCH (HORMONE DE CONCENTRATION EN MELANINE) POUR LE TRAITEMENT DE TROUBLES DUS A L'ALIMENTATION
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2005063239A1

  公开（公告）日：2005-07-14

  Die vorliegende Erfindung betrifft Amid-Verbindungen der allgemeinen Formel (I), in der die Gruppen und Reste A, B, b, W, X, Y, Z, R1, R2 und R3 die in Anspruch 1 angegebenen Bedeutungen aufweisen. Ferner betrifft die Erfindung Arzneimittel enthaltend mindestens ein erfindungsgemäßes Amid. Auf Grund der MCH-Rezeptor antagonistischen Aktivität eignen sich die erfindungsgemäßen Arzneimittel zur Behandlung von metabolischen Störungen und/oder Essstörungen, insbesondere von Adipositas, Bulimie, Anorexie, Hyperphagia und Diabetes.

  该发明涉及通式（I）的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中所述的含义。此外，该发明涉及含有至少一种根据本发明的酰胺的药物。由于MCH受体拮抗活性，根据本发明的药物适用于治疗代谢紊乱和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20050267093A1

  公开（公告）日：2005-12-01

  Compounds of formula (I) wherein A, B, b, W, X, Y, Z, R 1 , R 2 , and R 3 have the meanings given in claim 1, pharmaceutical compositions these compounds, and methods of preventing or treating metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes using these compounds.

  化合物的公式（I），其中A，B，b，W，X，Y，Z，R1，R2和R3具有权利要求1所给出的含义，制备这些化合物的药物组合物，以及使用这些化合物预防或治疗代谢紊乱和/或进食障碍，特别是肥胖症，暴食症，厌食症，暴饮暴食和糖尿病的方法。
• Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040152742A1

  公开（公告）日：2004-08-05

  The present invention relates to amide compounds of general formula I 1 wherein the groups and residues A, B, b, W, X, Y, Z, R 1 , R 2 and R 3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I1的酰胺化合物，其中基团和残基A、B、b、W、X、Y、Z、R1、R2和R3具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中一种酰胺的药物组合物。鉴于MCH受体拮抗活性，本发明中的药物组合物适用于治疗代谢性疾病和/或进食障碍，特别是肥胖症、暴食症、厌食症、过度进食和糖尿病。
• New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds
  申请人：Roth Juergen Gerald

  公开号：US20070111981A1

  公开（公告）日：2007-05-17

  The present invention relates to (hetero)aryl compounds of general formula I wherein the groups and radicals A, B, Q, W, X, Y, Z, R 1 , R 2 , R 4a , R 4b , R 5a , R 5b , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的（杂）芳基化合物，其中A、B、Q、W、X、Y、Z、R1、R2、R4a、R4b、R5a和R5b基团和基团具有权利要求1中给出的含义。此外，本发明涉及至少含有本发明中的一种化合物的制药组合物。由于其MCH受体拮抗活性，根据本发明的制药组合物适用于治疗代谢紊乱和/或进食障碍，尤其是肥胖症、贪食症、厌食症、暴食症和糖尿病。
• Thermally cured undercoat for lithographic application
  申请人：De B. Binod

  公开号：US20050238997A1

  公开（公告）日：2005-10-27

  Thermally curable undercoat composition comprising for producing a bilayer relief image comprising: a) a polymer of Structure I comprising repeating units of Structure II, III, and IV b) a phenolic crosslinker; c) a thermal acid generator (TAG); and d) a solvent.

  热固化底涂层组合物，包括用于制作双层浮雕图像的以下成分 a) 结构 I 的聚合物，包括结构 II、III 和 IV 的重复单元 b) 酚醛交联剂； c) 热酸发生器 (TAG)；以及 d) 溶剂。